ACAD Maintained by Deutsche Bank -- Price Target Raised to $38.00

gurufocus.com · 2026-08-25

On October 03, 2023, ACADIA Pharmaceuticals (ACAD) received a maintained 'Buy' rating from Deutsche Bank, with analyst David Hoang leading the assessment. Along

TickrTrends take: Deutsche Bank's price target raise to $38 comes amid TickrTrends' current overvalued assessment of ACAD, suggesting the market may already be pricing in positive expectations for the healthcare company. Investors tracking valuation metrics should monitor whether ACAD's fundamentals can justify closing the gap between current trading levels and Deutsche Bank's target, or whether the overvaluation verdict will persist. The analyst action provides a data point for reconciling with TickrTrends' valuation framework, particularly as healthcare sector dynamics continue to evolve.

Read the full story at gurufocus.com →